Generic drugs approved by FDA (through May 2011): bromfenac ophthalmic solution 0.09%, sodium ferric gluconate complex in sucrose injection, nitrofurantoin oral suspension
Bromfenac ophthalmic solution 0.09% (twice-daily administration) (equiv to Xibrom Ophthalmic Solution, 0.09% (Twice-Daily Administration)
MYLAN
Sodium ferric gluconate complex in sucrose injection (Nulecit) in 5-mL glass ampules (equiv to Ferrlecit)
WATSON
Nitrofurantoin Oral Suspension in 25 mg/5 mL strength (equiv to Furadantin)
AMNEAL
FDA Sets Date of Advisory Committee Meeting for Donanemab in Alzheimer’s Disease
May 7th 2024The Peripheral and Central Nervous System Drugs Advisory Committee will meet on Monday, June 10, 2024, to discuss the phase 3 trial of Lilly’s donanemab to treat patients with early symptomatic Alzheimer’s disease.
FDA Approves Xolremdi for Ultra Rare Immune Disorder
April 29th 2024Xolremdi is the first therapy for WHIM syndrome, which can cause recurrent lung infections and papillomavirus-related warts. It’s available in two doses: 400 mg for an annual cost of $496,400 and 300 mg for an annual cost of $372,300.